Linked Life Data

19649918

Source:http://linkedlifedata.com/resource/pubmed/id/19649918

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2009-8-3
pubmed:abstractText
The current trend in the pharmaceutical industry is to shorten the timelines for all aspects of drug discovery. Although several well-established methods are used for routine toxicological evaluation, new, innovative tools are being designed, developed and implemented that promise to deliver significant advantages. These include technologies that take advantage of large-scale mining of the genome and proteome, such as microarrays and two-dimensional electrophoresis, and methods that enhance the molecular detection of specific proteins and mRNAs, such as mass spectroscopy and branched DNA. These tools, combined with better in vitro model systems, will become instrumental in answering questions about the molecular mechanisms of toxicity, as well as offering productive and effective means for higher-throughput toxicity assessment.
pubmed:language
eng
pubmed:journal
pubmed:status
PubMed-not-MEDLINE
pubmed:month
Jan
pubmed:issn
1367-6733
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
58-68
pubmed:year
1999
pubmed:articleTitle
Emerging technologies for accelerated toxicity evaluation of potential drug candidates.
pubmed:affiliation
Chiron Corp, Emeryville, CA 94608, USA. marque_todd@cc.chiron.com
pubmed:publicationType
Journal Article